ecamsule
Trade name: Mexoryl SX
Approved
Jul 21, 2006
Also called Ecamsule (technical name terephthalylidine dicamphor sulfonic acid), Mexoryl SX is a synthetic sunscreen agent developed and patented by L’Oreal and used in the company’s sunscreen products sold outside the United States since 1993 (approved for use in Europe in 1991). Ecamsule affords broad spectrum protection against the sun’s UVB and UVA rays. Exposed to UV, ecamsule undergoes reversible photoisomerization, followed by photoexcitation. The absorbed UV is then released as thermal energy, without penetrating the skin. The UVB range is 280 to 320 nanometers, and the UVA range is 320 to 400. Ecamsule protects against UV wavelengths in the 290–400 nanometer range, with peak protection at 345 nm.[3][4] Since ecamsule doesn't cover the entire UV spectrum, it should be combined with other active sunscreen agents to ensure broad-spectrum UV protection. Ecamsule is a photostable organic UVA absorber, meaning it doesn't degrade significantly when exposed to light. — NCATS
Clinical trial activity
4 trials · 4 clinical orgs · 2 marketing orgs
Earliest trial started May 1, 2006 (NCT00326274)
Timeline
Indications
Mechanism of action
- Unspecified targetOTHER
Sunscreen
- Unspecified targetUltraviolet filter
ultraviolet filter
Combination products
anthelios
with titanium, octocrylene, avobenzone
anthelios sx
with octocrylene, avobenzone
Also known as capital soleil
Approval history
- approvedJul 21, 2006
Chemistry & pharmacology
SMILES
CC1(C)C2CCC1(CS(=O)(=O)O)C(=O)C2=Cc1ccc(C=C2C(=O)C3(CS(=O)(=O)O)CCC2C3(C)C)cc1- Mol. weight
- 562.71 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Racemic Mixture
- Inorganic
- No
- Polymer
- No
- Delivery
- Topical
- Availability
- Over the Counter
Oral
No
Parenteral
No
Topical
Yes
Sources
- ChEMBLCHEMBL3989850 ↗
- WikipediaEcamsule ↗
- NCATSM94R1PM439 ↗
- ChEMBLCHEMBL2096649 ↗
Also known as
- 3,3'-(1,4-phenylenedimethylidyne)bis(7,7-dimethyl-2-oxobicyclo(2.2.1)heptane-1-methanesulfonic acid)
- ((3z)-3-((4-((z)-(7,7-dimethyl-3-oxo-4-(sulfomethyl)norbornan-2-ylidene)methyl)phenyl)methylidene)-7,7-dimethyl-2-oxo-norbornan-1-yl)methanesulfonic acid
- ecamsule
- ecamsule
- ecamsule
- ecamsule
- ecamsule
- ecamsule
- ecamsule
- mexoryl
- mexoryl
- mexoryl sx
- mexoryl sx
- mexoryl sx
- mexoryl sx
- mexoryl sx
- mexoryl sx
- terephthalylidene dicamphor sulfonic acid
- terephthalylidene dicamphor sulfonic acid
- terephthalylidene dicamphor sulfonic acid
- terephthalylidene dicamphor sulfonic acid
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01695356 | Phase 4 | Sep 1, 2012 | Universidad Autonoma de San Luis Potosi |
| NCT00701740 | Phase 2 | Jul 1, 2007 | University of Sao Paulo |
| NCT00368563 | Phase 2/Phase 3 (Phase 3) | Aug 1, 2006 | Hill Top Research, L'Oreal |
| NCT00326274 | Phase 3 | May 1, 2006 | L'Oreal |
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| L'Oreal | For profit | 2 | 2 | 1 | 2006 |
| Hill Top Research | For profit | 1 | 0 | 1 | 2006 |
| Universidad Autonoma de San Luis Potosi | Academic/Hospital | 1 | 1 | 1 | 2012 |
| University of Sao Paulo | Academic/Hospital | 1 | 1 | 1 | 2007 |
Marketing (3)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| L'Oreal | For profit | NDA | Jul 21, 2006 |
| L'Oreal | For profit | NDA2 | Jul 21, 2006 |
| Sanofi-Aventis | For profit | NDA2 | Jul 21, 2006 |